Nov 06, 2026

EP-PerMed announced its call 2027 “Cell and Gene Therapy for Personalised Medicine”

The EP PerMed launched its joint transnational call 2027 (JTC2026) “Cell and Gene Therapy for Personalised Medicine” (CGT4PM). Aim of PerMed is to fund multinational, innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe and beyond in this field.

The call will be implemented in two stages, i.e. a pre- and a full proposal phase. The available budget for this call is 38 Mio. EUR (approx.).

Proposals must focus on the development and validation of an innovative and novel CGT for PM.

For this call, CGT are considered innovative and novel when they offer clear therapeutic advantages over the standard of care, such as improved efficacy, enhanced safety, longer-lasting effects, or the ability to address previously untreatable conditions.

At least one of the following approaches must be employed:

Somatic cell therapeutics (e.g., in the form of stem cells, organoids, or cells of the immune system);
Gene therapeutics in the form of gene substitution, addition or suppression therapies using viral and non-viral vectors or genome editing;
Combined cell- and gene therapeutics in the form of genetically modified cells;
Novel biological products such as mRNA, other nucleic acid-based methods, and extracel-lular vesicles as vehicle for gene-based therapeutic procedure.

The research projects have to use physiologically relevant preclinical models (e.g., human cell cul-tures, organoids, organs-on-chips, animal models). Furthermore, they have to show solid preliminary data (e.g., defined vector or cell system, existing preclinical model) and have to describe a credible pathway towards clinical application.

Important facts: